196 related articles for article (PubMed ID: 19900544)
41. Tamoxifen citrate loaded amphiphilic beta-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity.
Memisoglu-Bilensoy E; Vural I; Bochot A; Renoir JM; Duchene D; Hincal AA
J Control Release; 2005 Jun; 104(3):489-96. PubMed ID: 15911048
[TBL] [Abstract][Full Text] [Related]
42. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.
Shi B; Fang C; Pei Y
J Pharm Sci; 2006 Sep; 95(9):1873-87. PubMed ID: 16795003
[TBL] [Abstract][Full Text] [Related]
43. Complex of 9-nitro-camptothecin in hydroxypropyl-beta-cyclodextrin: in vitro and in vivo evaluation.
Jiang Y; Sha X; Zhang W; Fang X
Int J Pharm; 2010 Sep; 397(1-2):116-21. PubMed ID: 20637848
[TBL] [Abstract][Full Text] [Related]
44. PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer.
Zhang X; Gan Y; Gan L; Nie S; Pan W
J Pharm Pharmacol; 2008 Aug; 60(8):1077-87. PubMed ID: 18644200
[TBL] [Abstract][Full Text] [Related]
45. Estradiol sustained release from high affinity cyclodextrin hydrogels.
Rodriguez-Tenreiro C; Alvarez-Lorenzo C; Rodriguez-Perez A; Concheiro A; Torres-Labandeira JJ
Eur J Pharm Biopharm; 2007 Apr; 66(1):55-62. PubMed ID: 17081737
[TBL] [Abstract][Full Text] [Related]
46. Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization.
Kaiser J; Thiesen J; Krämer I
J Oncol Pharm Pract; 2010 Mar; 16(1):53-61. PubMed ID: 19617306
[TBL] [Abstract][Full Text] [Related]
47. Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations.
Miro A; Quaglia F; Sorrentino U; La Rotonda MI; D'Emmanuele Di Villa Bianca R; Sorrentino R
Eur J Pharm Sci; 2004 Sep; 23(1):57-64. PubMed ID: 15324923
[TBL] [Abstract][Full Text] [Related]
48. Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics.
Kim JH; Lee SK; Lim JL; Shin HJ; Hong CI
Int J Pharm; 2002 Jun; 239(1-2):207-11. PubMed ID: 12052706
[TBL] [Abstract][Full Text] [Related]
49. Encapsulation of Babchi Oil in Cyclodextrin-Based Nanosponges: Physicochemical Characterization, Photodegradation, and In Vitro Cytotoxicity Studies.
Kumar S; ; Trotta F; Rao R
Pharmaceutics; 2018 Sep; 10(4):. PubMed ID: 30261580
[TBL] [Abstract][Full Text] [Related]
50. Cyclodextrin-based nanosponges: A critical review.
Sherje AP; Dravyakar BR; Kadam D; Jadhav M
Carbohydr Polym; 2017 Oct; 173():37-49. PubMed ID: 28732878
[TBL] [Abstract][Full Text] [Related]
51. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
[TBL] [Abstract][Full Text] [Related]
52. Effect of hydroxypropyl-beta-cyclodextrin-complexation and pH on solubility of camptothecin.
Saetern AM; Nguyen NB; Bauer-Brandl A; Brandl M
Int J Pharm; 2004 Oct; 284(1-2):61-8. PubMed ID: 15454297
[TBL] [Abstract][Full Text] [Related]
53. Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67.
Joguparthi V; Xiang TX; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):400-20. PubMed ID: 17879989
[TBL] [Abstract][Full Text] [Related]
54. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
55. Cyclodextrin based nanosponge of norfloxacin: Intestinal permeation enhancement and improved antibacterial activity.
Mendes C; Meirelles GC; Barp CG; Assreuy J; Silva MAS; Ponchel G
Carbohydr Polym; 2018 Sep; 195():586-592. PubMed ID: 29805015
[TBL] [Abstract][Full Text] [Related]
56. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies.
Martins S; Tho I; Reimold I; Fricker G; Souto E; Ferreira D; Brandl M
Int J Pharm; 2012 Dec; 439(1-2):49-62. PubMed ID: 23046667
[TBL] [Abstract][Full Text] [Related]
57. Incorporation of camptothecin into N-phthaloyl chitosan-g-mPEG self-assembly micellar system.
Opanasopit P; Ngawhirunpat T; Chaidedgumjorn A; Rojanarata T; Apirakaramwong A; Phongying S; Choochottiros C; Chirachanchai S
Eur J Pharm Biopharm; 2006 Nov; 64(3):269-76. PubMed ID: 16870407
[TBL] [Abstract][Full Text] [Related]
58. Cyclodextrin-based nanosponges: a propitious platform for enhancing drug delivery.
Chilajwar SV; Pednekar PP; Jadhav KR; Gupta GJ; Kadam VJ
Expert Opin Drug Deliv; 2014 Jan; 11(1):111-20. PubMed ID: 24298891
[TBL] [Abstract][Full Text] [Related]
59. Influence of cyclodextrins on the proliferation of HaCaT keratinocytes in vitro.
Hipler UC; Schönfelder U; Hipler C; Elsner P
J Biomed Mater Res A; 2007 Oct; 83(1):70-9. PubMed ID: 17380497
[TBL] [Abstract][Full Text] [Related]
60. Hollow nanosphere fabricated from β-cyclodextrin-grafted α,β-poly(aspartic acid) as the carrier of camptothecin.
Zeng J; Huang H; Liu S; Xu H; Huang J; Yu J
Colloids Surf B Biointerfaces; 2013 May; 105():120-7. PubMed ID: 23376743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
